Microbix recapMicrobix Recap From IR firm on 7/7 (Adelaide) Microbix Biosystems (TSX: MBX) After 10 material news releases in a 6-week period in May/early June, Microbix took it a little easier on its Investor Relations team through the middle and later parts of June. The Company has achieved so many significant milestones throughout the pandemic, including the following: First shipment of COVID-19 quality assessment products (QAPs) to labs in Canada FDA registration for COVID-19 QAPs to be sold to labs in the US QAPs distribution agreement for Italy Reported Q2 results QAPs distribution agreement for Australia, Belgium, Canada, France, Germany, Luxembourg, Netherlands, New Zealand, Norway, Spain, and the United Kingdom Full utilization of its bioreactors for rubella antigens Buildout begun to expand its QAPs production capacity Engagement with an unnamed company to develop and supply custom QAPs to support the registration and sales of a new point-of-care instrument and its tests for viral respiratory pathogens QAPs distribution agreement for the US EU CE Mark Registration (i.e., European approval) attained for its COVID-19 QAPs Why we like Microbix MBX is cash-flow and EBITDA positive, with revenues of > $13M per year. The core business is growing at 10% to 20%, propelled by expansion in new markets (primarily Asia), plus the Company has seen material growth in its QAPs business. The Company launched a new QAPs product line with approvals in Canada, the US and Europe and distribution in 22 countries in a very short time, showing its nimbleness and effectiveness in meeting the dynamic and challenging demands of the international healthcare landscape. The Company is well funded to expand its QAPs, and these new markets should represent material revenue growth. Technological advances are driving the increased production and corporate profitability that MBX has guided to achieving in 2020. Kinlytic urokinase, a clot-buster biologic drug that has existing approvals from the U.S. FDA and Health Canada, provides optionality. MBX is currently looking to partner this drug, which in a massive market could represent > $200M in sales.